Industry
Biotechnology
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
February 07, 2024 | 2:58 pm
Portfolio Pulse from Benzinga Insights
February 07, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
January 29, 2024 | 12:23 pm
Portfolio Pulse from Benzinga Insights
January 15, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Insights
December 27, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
December 05, 2023 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
December 04, 2023 | 2:57 pm
Portfolio Pulse from Benzinga Insights
October 09, 2023 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
September 25, 2023 | 11:02 am
Portfolio Pulse from Happy Mohamed
August 29, 2023 | 1:10 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.